Arcutis Biotherapeutics, Inc.
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
About
CEO
Mr. Todd Franklin Watanabe M.A.
Employees
296
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
3027 Townsgate Road, Westlake Village, CA 91361, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 4, 2025 | — | — | — | — |
| Aug 12, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Feb 25, 2025 | -0.28 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 7 |
| Average estimate | — | -0.28 | — | -0.85 |
| Low estimate | — | -0.30 | — | -1.13 |
| High estimate | — | -0.25 | — | -0.52 |
| Last year EPS | — | -0.32 | — | -1.34 |
[stock_revenue_estimate]
Growth estimates
Current qtr
63.290%
Next qtr. (Mar 2025)
11.460%
Current year
64.550%
Next year (Dec 2025)
36.350%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 59.61M | 3.69M | — | — | — |
| Cost of revenue | 4.99M | 754,000 | — | — | — |
| Gross profit | 54.62M | 2.93M | — | — | — |
| Operating expense | |||||
| Research & development | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M |
| Selling general and admin | 185.15M | 122.12M | 60.97M | 21.34M | 6.61M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 29.71M | 15.65M | — | — | — |
| Other income expense | 11.79M | 5.82M | 173,000 | 967,000 | 1.14M |
| Pretax income | -259.03M | -311.46M | -206.36M | -135.68M | -42.00M |
| Tax provision | 3.11M | — | — | — | — |
| Net income | -262.14M | -311.46M | -206.36M | -135.68M | -42.00M |
| Basic EPS | -3.78 | -5.66 | -4.18 | -3.80 | -1.20 |
| Diluted EPS | -3.78 | -5.66 | -4.18 | -3.80 | -1.20 |
| Basic average shares | 69.31M | 55.03M | 49.41M | 35.67M | 35.06M |
| Diluted average shares | 69.31M | 55.03M | 49.41M | 35.67M | 35.06M |
| EBITDA | -227.79M | -294.87M | -205.90M | -135.56M | -43.06M |
| Net income from continuing op. | -262.14M | -311.46M | -206.36M | -135.68M | -42.00M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 341.37M | 449.27M | 408.15M | 298.27M | 107.01M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | 88.40M | 53.64M | 96.45M | 65.08M | 63.34M |
| Cash and cash equivalents | 88.40M | 53.64M | 96.45M | 65.08M | 63.34M |
| Other short term investments | 183.46M | 355.95M | 290.61M | 219.36M | 37.93M |
| Accounts receivable | 25.81M | 8.46M | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | 13.13M | 7.51M | — | — | — |
| Prepaid assets | 10.50M | 4.35M | 6.15M | 6.33M | 3.32M |
| Restricted cash | 925,000 | 1.23M | 1.54M | 1.54M | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 8.21M | 6.26M | 8.03M | — | — |
| Non current assets | |||||
| Properties | 2.36M | 2.72M | 3.04M | 3.35M | 227,000 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 1.90M | 1.47M | 1.23M | 516,000 | 404,000 |
| Construction in progress | — | — | — | 298,000 | — |
| Leases | 1.57M | 1.57M | 1.57M | 1.28M | 155,000 |
| Accumulated depreciation | -1.92M | -1.15M | -532,000 | -78,000 | -68,000 |
| Goodwill | 6.44M | 7.19M | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 596,000 | 78,000 | 78,000 | 78,000 | 47,000 |
| Total liabilities | 252.70M | 239.69M | 110.48M | 27.65M | 172.04M |
| Current liabilities | |||||
| Accounts payable | 11.99M | 8.83M | 7.35M | 7.14M | 1.41M |
| Accrued expenses | 19.07M | 14.32M | 16.41M | 11.03M | 2.28M |
| Short term debt | 735,000 | 657,000 | 433,000 | — | 178,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 14.87M | 14.00M | 9.13M | 4.43M | 1.38M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 205.18M | 201.89M | 77.12M | 4.96M | 129,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 849,000 | — | 25,000 | 82,000 | 184,000 |
| Shareholders equity | |||||
| Common stock | 9,000 | 6,000 | 5,000 | 4,000 | — |
| Retained earnings | -981.90M | -719.76M | -408.31M | -201.95M | -66.27M |
| Other shareholders equity | 4,000 | -1.09M | -255,000 | -2,000 | -1,000 |
| Total shareholders equity | 88.67M | 209.58M | 297.68M | 270.62M | -65.03M |
| Additional paid in capital | 1.07B | 930.43M | 706.23M | 472.57M | 1.24M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | -262.14M | -311.46M | -206.36M | -135.68M | -42.00M | -19.26M | -4.98M |
| Depreciation | 1.52M | 934,000 | 454,000 | 122,000 | 68,000 | — | — |
| Deferred Taxes | — | — | — | — | — | — | — |
| Stock-Based Compensation | 38.81M | 32.68M | 23.89M | 7.94M | 824,000 | 151,000 | 27,000 |
| Other Non-Cash Items | 4.39M | 32.56M | 309,000 | 333,000 | 127,000 | 2.93M | 747,000 |
| Accounts Receivable | -17.35M | -8.46M | — | — | — | — | — |
| Accounts Payable | 3.15M | 1.57M | 245,000 | 5.67M | -458,000 | 1.26M | 537,000 |
| Other Assets & Liabilities | -6.28M | -7.95M | 243,000 | -6,000 | -131,000 | — | — |
| Operating Cash Flow | -237.89M | -260.13M | -181.21M | -121.61M | -41.57M | -14.92M | -3.67M |
| Investing Activities | |||||||
| Capital Expenditures | -428,000 | -333,000 | -995,000 | -321,000 | -295,000 | — | — |
| Net Intangibles | — | -22.95M | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — |
| Purchase of Investments | -225.84M | -415.39M | -292.51M | -279.10M | -60.83M | -11.53M | — |
| Sale of Investments | 406.50M | 351.47M | 217.55M | 97.60M | 34.80M | — | — |
| Investing Cash Flow | 180.23M | -64.25M | -75.95M | -181.82M | -26.33M | -11.53M | — |
| Financing Activities | |||||||
| Long-Term Debt Issuance | — | 125.00M | 73.99M | — | — | — | 50,000 |
| Long-Term Debt Payments | — | — | — | — | — | — | — |
| Other Financing Charges | — | -2.19M | -1.64M | — | -1.40M | — | — |
| Financing Cash Flow | 98.90M | 298.86M | 279.84M | 297.00M | 92.84M | 61.21M | 7.12M |
| Other Cash Details | |||||||
| End Cash Position | 89.32M | 54.88M | 97.99M | 66.62M | 63.34M | 39.39M | 3.42M |
| Income Tax Paid | — | — | — | — | — | — | — |
| Interest Paid | 25.45M | 12.64M | 142,000 | — | — | — | — |
| Free Cash Flow | -247.49M | -281.00M | -175.62M | -113.35M | -43.13M | -14.09M | -3.78M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 3,589,510 | 47.31M | 3.07% |
| PGIM Jennison Small Company Fd | Nov 30, 2024 | 3,085,198 | 40.66M | 2.64% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 3,022,426 | 39.84M | 2.58% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 2,980,488 | 39.28M | 2.55% |
| PGIM Jennison Health Sciences Fd | Nov 30, 2024 | 2,735,010 | 36.05M | 2.34% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 1,606,008 | 21.17M | 1.37% |
| Franklin Strategic Series-Franklin Biotechnology Discove | Oct 31, 2024 | 1,525,545 | 20.11M | 1.30% |
| American Century Small Cap Growth Fund | Oct 31, 2024 | 1,283,621 | 16.92M | 1.10% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 1,086,544 | 14.32M | 0.93% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 954,383 | 12.58M | 0.82% |
Article
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year. The post Arcutis Soared In 2024, Blazing Trails In Dermatology.
Feb 6, 2025
Article
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 62,000 restricted stock units of Arcutis' common stock to eight newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Feb 5, 2025
Article
Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"
Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is sharing his experience with ZORYVE® (roflumilast) topical foam, 0.3%, to help others learn more about this chronic inflammatory skin condition ZORYVE foam is a once-daily, steroid-free, topical for seborrheic dermatitis uniquely formulated for use anywhere on the body, including hair-bearing areas Seborrheic dermatitis impacts more than 10 million Americans and is the third most common skin condition affecting Blacks WESTLAKE VILLAGE, Calif. , Feb. 4, 2025 /PRNewswire/ -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a partnership with the iconic professional football player, Odell Beckham Jr. ("OBJ"), to help raise awareness of seborrheic dermatitis ("seb derm") a common, chronic, recurrent inflammatory skin disease that can cause flaking, redness, itching, and discoloration of the skin.
Feb 4, 2025
